Rituximab
- Generic Name
- Rituximab
- Brand Names
- MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 174722-31-7
- Unique Ingredient Identifier
- 4F4X42SYQ6
- Background
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...
- Indication
Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...
- Associated Conditions
- Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)
- Associated Therapies
- -
Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout
- First Posted Date
- 2023-12-29
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 9
- Registration Number
- NCT06186219
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Mabscale, LLC
- Target Recruit Count
- 208
- Registration Number
- NCT06175338
- Locations
- 🇷🇺
LLC "Medical Center Revma-Med", Kemerovo, Russian Federation
🇷🇺LLC "Korolev Family Clinic №4", Korolev, Russian Federation
🇷🇺JSC "Northwestern Center for Evidence-Based Medicine", Saint-Petersburg, Russian Federation
A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 470
- Registration Number
- NCT06149286
- Locations
- 🇩🇪
Clinic Frankfurt (Oder), Frankfurt, Hesse, Germany
🇹🇷Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT06136351
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Indapta Therapeutics, INC.
- Target Recruit Count
- 128
- Registration Number
- NCT06119685
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center, Lake Mary, Florida, United States
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 733
- Registration Number
- NCT06097364
- Locations
- 🇨🇱
Hospital Clinico Universidad de Los Andes, Santiago, Las Condes, Chile
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 904
- Registration Number
- NCT06091865
- Locations
- 🇫🇷
Hopital Saint Vincent-de-Paul, Lille, Nord, France
🇰🇷St. Vincent Hospital - The Catholic University of Korea, Suwon-si, Gyeonggi-do, Korea, Republic of
🇰🇷Yeouido St. Marys Hospital, Seoul, Korea, Republic of
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 273
- Registration Number
- NCT06090539
- Locations
- 🇩🇪
Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 478
- Registration Number
- NCT06091254
- Locations
- 🇪🇸
Hospital Clinico Universitario Valencia, Valencia, Spain
🇪🇸Hospital Universitary and Politecnic La Fe, Valencia, Spain
🇨🇭Kantonsspital Baden, Baden, Aargau, Switzerland
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT06084936
- Locations
- 🇦🇺
Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia
🇦🇺Royal Adelaide Hospital; Haematology Clinical Trials, Adelaide, South Australia, Australia
🇦🇺Epworth Hospital, Richmond, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.